PRO 303
Alternative Names: PRO-303; R-VECs + Donor Islets - ProterrisLatest Information Update: 07 Nov 2023
At a glance
- Originator Proterris
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 21 Jul 2023 Proterris intends to submit IND application for Type 1 diabetes mellitus by 2024 (Proterris pipeline, July 2023)
- 13 Jul 2023 Preclinical trials in Type 1 diabetes mellitus in USA (SC) (Proterris pipeline, July 2023)